Drug Price Watchdog Making Unfair Decisions, Indian Industry Lobby Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Lack of transparency in price setting, misapplication of the Spurious Drugs law and a new requirement that already-approved fixed-dose combinations be treated as new drugs are high on the grievance list.